Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 14.35 Billion KRW | -38.59% |
| 2022 | 40.4 Billion KRW | -1.51% |
| 2021 | 41.02 Billion KRW | 20.3% |
| 2020 | 34.1 Billion KRW | 4.89% |
| 2019 | 32.51 Billion KRW | 94.42% |
| 2018 | 16.72 Billion KRW | -31.56% |
| 2017 | 24.43 Billion KRW | 5.4% |
| 2016 | 23.18 Billion KRW | 49.41% |
| 2015 | 15.51 Billion KRW | 148.42% |
| 2014 | 6.24 Billion KRW | 31.95% |
| 2013 | 4.73 Billion KRW | 46.66% |
| 2012 | 3.22 Billion KRW | -14.81% |
| 2011 | 3.78 Billion KRW | -36.03% |
| 2010 | 5.92 Billion KRW | -9.98% |
| 2009 | 6.57 Billion KRW | 154.87% |
| 2008 | -11.99 Billion KRW | -7556.92% |
| 2007 | 160.81 Million KRW | -97.31% |
| 2006 | 5.97 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.68 Billion KRW | -5.86% |
| 2024 Q1 | 2.85 Billion KRW | -69.97% |
| 2023 Q4 | 9.5 Billion KRW | 19.65% |
| 2023 Q1 | 4.48 Billion KRW | -22.19% |
| 2023 Q3 | 7.94 Billion KRW | 176.71% |
| 2023 Q2 | 2.87 Billion KRW | -35.95% |
| 2023 FY | 24.81 Billion KRW | -38.59% |
| 2022 Q1 | 11.1 Billion KRW | -21.47% |
| 2022 FY | 40.4 Billion KRW | -1.51% |
| 2022 Q4 | 5.76 Billion KRW | -55.75% |
| 2022 Q3 | 13.02 Billion KRW | 45.64% |
| 2022 Q2 | 8.94 Billion KRW | -19.45% |
| 2021 Q2 | 6.17 Billion KRW | -24.95% |
| 2021 Q1 | 8.22 Billion KRW | -1.11% |
| 2021 FY | 41.02 Billion KRW | 20.3% |
| 2021 Q4 | 14.13 Billion KRW | 13.14% |
| 2021 Q3 | 12.49 Billion KRW | 102.52% |
| 2020 Q2 | 7.54 Billion KRW | 10.25% |
| 2020 Q4 | 8.31 Billion KRW | -27.07% |
| 2020 Q3 | 11.4 Billion KRW | 51.13% |
| 2020 Q1 | 6.84 Billion KRW | 12.21% |
| 2020 FY | 34.1 Billion KRW | 4.89% |
| 2019 Q1 | 9.7 Billion KRW | 1014.04% |
| 2019 FY | 32.51 Billion KRW | 94.42% |
| 2019 Q4 | 6.09 Billion KRW | -31.65% |
| 2019 Q3 | 8.92 Billion KRW | 14.58% |
| 2019 Q2 | 7.78 Billion KRW | -19.79% |
| 2018 Q1 | 8.55 Billion KRW | 21.3% |
| 2018 FY | 16.72 Billion KRW | -31.56% |
| 2018 Q2 | 5.1 Billion KRW | -40.31% |
| 2018 Q3 | 2.18 Billion KRW | -57.29% |
| 2018 Q4 | 871.3 Million KRW | -60.07% |
| 2017 Q3 | 5.98 Billion KRW | 9.28% |
| 2017 FY | 24.43 Billion KRW | 5.4% |
| 2017 Q1 | 5.91 Billion KRW | -7.95% |
| 2017 Q2 | 5.47 Billion KRW | -7.42% |
| 2017 Q4 | 7.05 Billion KRW | 17.92% |
| 2016 Q3 | 5.19 Billion KRW | 23.37% |
| 2016 Q4 | 6.42 Billion KRW | 23.63% |
| 2016 Q1 | 7.34 Billion KRW | 0.0% |
| 2016 Q2 | 4.21 Billion KRW | -42.64% |
| 2016 FY | 23.18 Billion KRW | 49.41% |
| 2015 Q3 | 2.52 Billion KRW | -57.99% |
| 2015 Q1 | 3.73 Billion KRW | 70.69% |
| 2015 FY | 15.51 Billion KRW | 148.42% |
| 2015 Q2 | 6.01 Billion KRW | 61.08% |
| 2014 Q2 | 115.41 Million KRW | -62.96% |
| 2014 Q1 | 311.59 Million KRW | -88.07% |
| 2014 FY | 6.24 Billion KRW | 31.95% |
| 2014 Q4 | 2.18 Billion KRW | 926.59% |
| 2014 Q3 | 212.94 Million KRW | 84.51% |
| 2013 FY | 4.73 Billion KRW | 46.66% |
| 2013 Q1 | -470.42 Million KRW | -129.97% |
| 2013 Q2 | 1.06 Billion KRW | 325.94% |
| 2013 Q3 | 746.24 Million KRW | -29.79% |
| 2013 Q4 | 2.61 Billion KRW | 250.11% |
| 2012 Q1 | -1.12 Billion KRW | -178.79% |
| 2012 Q2 | 1.56 Billion KRW | 239.5% |
| 2012 Q3 | 814.28 Million KRW | -48.11% |
| 2012 FY | 3.22 Billion KRW | -14.81% |
| 2012 Q4 | 1.56 Billion KRW | 92.75% |
| 2011 Q2 | 1.36 Billion KRW | 88.4% |
| 2011 Q1 | 722.97 Million KRW | -67.45% |
| 2011 FY | 3.78 Billion KRW | -36.03% |
| 2011 Q4 | 1.42 Billion KRW | -32.78% |
| 2011 Q3 | 2.12 Billion KRW | 55.92% |
| 2010 Q3 | 1.97 Billion KRW | 95.71% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 5.92 Billion KRW | -9.98% |
| 2010 Q2 | 1 Billion KRW | 0.0% |
| 2010 Q4 | 2.22 Billion KRW | 12.65% |
| 2009 Q1 | -5.99 Billion KRW | -5137.84% |
| 2009 FY | 6.57 Billion KRW | 154.87% |
| 2009 Q4 | 169.78 Million KRW | -76.74% |
| 2009 Q3 | 730.05 Million KRW | -10.21% |
| 2009 Q2 | 813.05 Million KRW | 113.56% |
| 2008 Q4 | 119.03 Million KRW | 116.55% |
| 2008 FY | -11.99 Billion KRW | -7556.92% |
| 2008 Q3 | -719.12 Million KRW | 86.67% |
| 2008 Q2 | -5.39 Billion KRW | -60.99% |
| 2008 Q1 | -3.35 Billion KRW | -439.68% |
| 2007 Q2 | 1.11 Billion KRW | 0.0% |
| 2007 Q4 | 986.55 Million KRW | -30.18% |
| 2007 FY | 160.81 Million KRW | -97.31% |
| 2007 Q3 | 1.41 Billion KRW | 27.04% |
| 2006 FY | 5.97 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3836.615% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 81.334% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 118.037% |
| HANDOK Inc. | 12.57 Billion KRW | -14.084% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 821.437% |
| Yuhan Corporation | 74.56 Billion KRW | 80.754% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -28.376% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 179.537% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 93.619% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -369.573% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -2306.163% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -1388.995% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 46.912% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3836.615% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 285.022% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -255.769% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 120.515% |
| JW Holdings Corporation | 143.66 Billion KRW | 90.011% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 126.865% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 94.181% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 85.693% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 130.28% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -107.169% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -121.764% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -64.355% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -3836.615% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 70.574% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 89.243% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 85.693% |
| Yuhan Corporation | 74.56 Billion KRW | 80.754% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 31.404% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -360.334% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 66.623% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 85.693% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 29.944% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 73.884% |
| CKD Bio Corp. | -20.15 Billion KRW | 171.209% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 55.479% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 43.284% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 55.879% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 130.28% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 56.707% |
| Boryung Corporation | 68.26 Billion KRW | 78.979% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 138.271% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 0.0% |
| JW Lifescience Corporation | 32.09 Billion KRW | 55.283% |